Searchable abstracts of presentations at key conferences in endocrinology

ea0020p194 | Endocrine tumours and neoplasia | ECE2009

Impact of surgery on clinical outcome in patients with recurrence of adrenocortical carcinoma

Erdogan Ilknur , Hahner Stefanie , Johanssen Sarah , Fenske Wiebke , Quinkler Marcus , Willenberg Holger S , Beuschlein Felix , Brix David , Allolio Bruno , Fassnacht Martin

Introduction: The role of surgery for recurrent ACC is not well defined. Therefore, we used the German ACC Registry to evaluate treatment modalities after first recurrence in patients amenable to surgery.Methods: Patients with recurrence after radical resection and follow-up data were included. Patients with extensive metastasized disease (>2 tumoral organs, peritoneal carcinomatosis) were excluded. Progression-free and overall survival (PFS/OS) were...

ea0016s30.3 | Clinical highlights | ECE2008

[123I]Iodometomidate as a radiotracer for diagnosis of adrenal tumours and adrenocortical carcinoma

Hahner Stefanie , Schirbel Andreas , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Beuschlein Felix , Quinkler Marcus , Reincke Martin , Stuermer Andrea , Reiners Christoph , Allolio Bruno

Subject: Adrenal tumours (AT) are often detected incidentally and represent a variety of differential diagnoses with variable therapeutic consequences. We have recently developed [123I]Iodometomidate ([123I]IMTO), that specifically binds to adrenal CYP11B enzymes as a SPECT tracer for adrenal scintigraphy. This radiotracer is now evaluated in patients with adrenal tumours in an ongoing clinical trial. The study was approved by the ethical committee and pa...

ea0014p145 | (1) | ECE2007

Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma – results of pre-clinical studies

Fassnacht Martin , Hahner Stefanie , Heinrich Barbara , Adam Patrick , Johanssen Sarah , Quinkler Marcus , Koschker Ann-Cathrin , Stroebel Philipp , Marx Alexander , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare malignancy with incompletely understood pathogenesis and poor prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been demonstrated in several tumors and is partly associated with a more aggressive phenotype and a worse prognosis. In addition, targeting the EGFR tyrosine kinase represents a successful new therapeutic strategy, e.g. in non-small cell lung cancer. Therefore, we investigated the role of EGF...

ea0056p134 | Endocrine tumours and neoplasia | ECE2018

Mesenchymal tissue markers as potential drug targets in adrenocortical tumours

Sbiera Iuliu , Altieri Barbara , Feuchtinger Annette , Kircher Stefan , Hofner Kerstin , Walch Axel Karl , Fassnacht Martin , Ronchi Cristina L , Kroiss Matthias , Sbiera Silviu

Introduction: Adrenocortical carcinoma (ACC) is a rare, aggressive tumour with unsatisfactory treatment options in advanced disease. Activation of epithelial to mesenchymal transition (EMT) has been described as causative of metastatic spread in a variety of human cancers. Accordingly, new drugs were developed specifically targeting EMT with a focus on HGF/c-MET and FGF/FGFR signalling. We here asked whether EMT is a relevant mechanism in ACC.Methods: Ex...

ea0073oc11.3 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma (ACC)

Kimpel Otilia , Paul Schindler , Bülent Polat , Megerle Felix , Haak Harm R. , Pittaway James , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

BackgroundThe ESE-ENSAT guidelines emphasize the role of local therapies and suggest radiotherapy (RT) as an individualized treatment in patients with advanced ACC. However, the evidence for this recommendation is very low. The aim of this study was to retrospectively investigate the efficacy and tolerance of radiation therapy in advanced ACC.MethodsWe screened all patients in five European reference centers ...

ea0073aep838 | Late Breaking | ECE2021

Consecutive development of adrenal Cushing´s syndrome and Cushing´s disease in a female patient with somatic CTNNB1, USP8, and NR3C1 mutations

Detomas Mario , Altieri Barbara , Schlötelburg Wiebke , Appenzeller Silke , Sven-Martin Schlaffer , Roland Coras , Andreas Schirbel , Wild Vanessa , Kroiss Matthias , Sbiera Silviu , Fassnacht Martin , Deutschbein Timo

ContextThe occurrence of different subtypes of endogenous Cushing’s syndrome (CS) in single individuals is extremely rare. We here present the case of a female patient who was successfully cured from adrenal CS 4 years before being diagnosed with Cushing’s disease (CD).Case DescriptionA 50-year-old female was diagnosed with ACTH-independent CS and a left-sided adrenal adenoma in January 2015. After ...

ea0075p13 | Pituitary and neuroendocrinology | EYES2021

Consecutive adrenal cushing´s syndrome and cushing´s disease in a patient with somatic CTNNB1, USP8, and NR3c1 mutations

Detomas Mario , Altieri Barbara , Schlotelburg Wiebke , Appenzeller Silke , Schlaffer Sven , Coras Roland , Schirbel Andreas , Wild Vanessa , Kroiss Matthias , Sbiera Silviu , Fassnacht Martin , Deutschbein Timo

Context: The occurrence of different subtypes of endogenous Cushing’s syndrome (CS) in single individuals is extremely rare. We here present the case of a female patient who was successfully cured from adrenal CS 4 years before being diagnosed with Cushing's disease (CD).Case Description: A 50-year-old female was diagnosed with ACTH-independent CS and a left-sided adrenal adenoma in January 2015. After adrenalectomy and histopathological co...

ea0093oc20 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

ROR-1 specific CAR-T cells with CRISPR/CAS9 mediated glucocorticoid receptor-knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma

Schauer Marc Philipp , Altieri Barbara , Redondo-Frutos Rodrigo A , Spieler Peter , Maier Tanja , Oppelt Daniel , Kroiss Matthias , Sbiera Silviu , Weber Justus , Fassnacht Martin , Landwehr Laura-Sophie , Hudecek Michael

# These authors contributed equallyIntroduction: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and limited treatment options. In addition, ACC is characterized by endogenous glucocorticoid (GC) excess in 60% of cases which is hypothesized to be one reason, why first clinical trials evaluating the potency of immune checkpoint blockade showed only modest results. Here, we report the identificati...

ea0093oc35 | Oral communication 5: Reproductive Endocrinology | EYES2023

Alteration of adrenal and sex steroid profiles in pregnant women with preeclampsia

Trummer Olivia , Stern Christina , Reintar Sharmaine , Tandl Veronika , Mayer-Pickel Karoline , Cervar-Zivkovic Mila , Fassnacht Martin , Kurlbaum Max , Huppertz Berthold , Fluhr Herbert , Obermayer-Pietsch Barbara

Background: Preeclampsia (PE) is a serious and complex pregnancy-related condition, characterized by hypertension and endothelial dysfunction, which can potentially damage liver, brain and kidneys, resulting to an increased perinatal morbidity and mortality. We investigated pregnancy-related steroid hormones such as progestogens, estrogens, androgens, and glucocorticoids to assess maternal and fetal development. We aim to compare steroid hormone profiles throughout pregnancy, ...

ea0099oc7.1 | Oral Communications 7: Endocrine-related Cancer | ECE2024

CRISPR/Cas9-mediated glucocorticoid receptor knockout effectively enhances antitumor efficacy of ROR1 specific CAR-T cells in advanced adrenocortical carcinoma

Schauer Marc Philipp , Weber Justus , Landwehr Laura-Sophie , Spieler Peter , Altieri Barbara , Maier Tanja , Kroiss Matthias , Kircher Stefan , Kurlbaum Max , Tony Liz , Sbiera Silviu , Fassnacht Martin , Hudecek Michael

Background: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and very limited treatment options in advanced disease. The only curative approach is complete surgical resection. Additionally, 60% of patients show endogenous glucocorticoid (GC) excess with clinical apparent hypercortisolism and low to no immune cell infiltration. To date, no therapeutically relevant surface markers are known for ACC, which is why it has not been con...